Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb repressive complex 2 via an H3K27M-like mechanism.

Piunti A, Smith ER, Morgan MAJ, Ugarenko M, Khaltyan N, Helmin KA, Ryan CA, Murray DC, Rickels RA, Yilmaz BD, Rendleman EJ, Savas JN, Singer BD, Bulun SE, Shilatifard A.

Sci Adv. 2019 Jul 3;5(7):eaax2887. doi: 10.1126/sciadv.aax2887. eCollection 2019 Jul.

2.

PAF1 regulation of promoter-proximal pause release via enhancer activation.

Chen FX, Xie P, Collings CK, Cao K, Aoi Y, Marshall SA, Rendleman EJ, Ugarenko M, Ozark PA, Zhang A, Shiekhattar R, Smith ER, Zhang MQ, Shilatifard A.

Science. 2017 Sep 22;357(6357):1294-1298. doi: 10.1126/science.aan3269. Epub 2017 Aug 31.

3.

Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent.

Cutts SM, Rephaeli A, Nudelman A, Ugarenko M, Phillips DR.

Curr Top Med Chem. 2015;15(14):1409-22. Review.

PMID:
25866273
4.

ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts.

Ugarenko M, Nudelman A, Rephaeli A, Kimura K, Phillips DR, Cutts SM.

Biochem Pharmacol. 2010 Feb 1;79(3):339-49. doi: 10.1016/j.bcp.2009.09.004. Epub 2009 Sep 6.

PMID:
19737541
5.

Development of pluronic micelle-encapsulated doxorubicin and formaldehyde-releasing prodrugs for localized anticancer chemotherapy.

Ugarenko M, Chan CK, Nudelman A, Rephaeli A, Cutts SM, Phillips DR.

Oncol Res. 2009;17(7):283-99.

PMID:
19408574

Supplemental Content

Loading ...
Support Center